Evidence map›Paper›PMID 28698788›Full record

ReviewMediterranean journal of hematology and infectious diseases2017

Treatment of Low-Blast Count AML using Hypomethylating Agents.

Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti and 4 more

Abstract readReview
In one paragraph

Review in Mediterranean journal of hematology and infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Eleonora De BellisHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Luana FianchiDepartment of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy.
Francesco BuccisanoHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Marianna CriscuoloDepartment of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy.
Luca MaurilloHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Laura CicconiHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Mattia BresciniHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Maria Ilaria Del PrincipeHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Ambra Di VeroliHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Adriano VendittiHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Sergio AmadoriHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
William ArceseHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Francesco Lo-CocoHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Maria Teresa VosoHematology, Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS). However, this AML subtype, defined as low-blast count AML (LBC-AML, with 20-30% BM-blasts) is characterized by peculiar features, as increased frequency in elderly individuals and after cytotoxic treatment for a different primary disease (therapy-related), poor-risk cytogenetics, lower white blood cell counts, and less frequent mutations of

Indexed as

AMLazacitidinedecitabineMDS

Identifiers

PMID28698788
PMCPMC5499495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.